Zacks Research Has Pessimistic Outlook of TBPH Q1 Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for Theravance Biopharma in a research note issued on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn ($0.43) per share for the quarter, down from their prior estimate of ($0.36). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.29) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at ($1.13) EPS and FY2027 earnings at ($0.96) EPS.

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $13.75.

Theravance Biopharma Stock Performance

Shares of TBPH stock opened at $9.31 on Monday. The firm has a market capitalization of $460.58 million, a price-to-earnings ratio of -9.22 and a beta of 0.15. The stock’s 50-day simple moving average is $9.36 and its 200-day simple moving average is $9.08. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $29.90 million.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This trade represents a 1.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Large investors have recently made changes to their positions in the business. Barclays PLC lifted its position in Theravance Biopharma by 279.9% during the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock valued at $529,000 after purchasing an additional 48,316 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Theravance Biopharma by 2.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock valued at $2,151,000 after buying an additional 7,620 shares during the last quarter. Algert Global LLC acquired a new position in shares of Theravance Biopharma in the 3rd quarter valued at about $851,000. Jane Street Group LLC boosted its stake in shares of Theravance Biopharma by 1.1% in the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock worth $1,165,000 after buying an additional 1,640 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Theravance Biopharma by 88.9% during the third quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after acquiring an additional 143,781 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.